Sections of tumors.

<p>Staining: HES; Iron in black. Magnification: x50: Group 1 (treated); x5: Group 2 (nanoparticles, no MFG) and Group 4 (no MFG, no nanoparticles).</p

Sampling of tumors during the experimentation.

<p>Sampling of tumors during the experimentation.</p

D 59+ tumors.

<p>Boxplot of tumor volume (mm^<b>3</b>) in the treatment group (1) and the three control groups (2 to 4). The bottom and top of the blue box are the first and third quartiles, and the horizontal rule inside the box is the second quartile (median). Whiskers correspond to ± 1.5 IQR (interquartile range). Means are plotted with an open diamond.</p

Evolution of the growth of tumors between D 0 (graft) to D74 (last sacrifices).

<p>Divergence begins on D 31 at the end of the treatment.</p

Groups at randomization; Total number of tumors: 84.

<p>Groups at randomization; Total number of tumors: 84.</p

Effect of a magnetic field gradient on <i>in vivo</i> tumor volume and <i>ex vivo</i> on its left and right surface areas.

<p>Volumes are expressed in mm³ and surface areas in mm²</p

The distribution of non-analyzable section by group.

<p>The distribution of non-analyzable section by group.</p

Proof of Concept: physical feasibility <i>in vivo</i>.

<p>Spreading of the nanoparticles around a subcutaneous grafted tumor 21 days after injection of a nanoparticles/MDA MB 231 cell mix; Tumor in pink (HES), iron in black.</p

Comparison between surfaces.

<p>A: Bloxpot of left tumor surface in treatment group (1) and the three control groups (2 to 4). The bottom and top of the blue box are the first and third quartiles and the horizontal rule inside the box is the second quartile (median). Whiskers correspond to ± 1.5 IQR (interquartile range). Data not included between the whiskers are plotted as outliers with an open circle. Means are plotted with an open diamond. B: Boxplot of right surface.</p

Patient and tumor characteristics.

<p>Patient and tumor characteristics.</p